person · Reporting owner

Schuetz Thomas J.

Disclosed activity across 2 companies

Tapewire entity: 67048
SEC CIK: 0001591464

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Compass Therapeutics, Inc.CMPX · Entity 5614	Director · CHIEF EXECUTIVE OFFICER	February 08, 2026	February 10, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Compass Therapeutics, Inc.

Report date February 08, 2026 · Filed February 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	6,603,336	Reported balance After 2026-02-08 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-02-08 · Tax withholding · Disposed 36,687 · Balance 6,603,336 F1: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F2: 125,000 of the shares represent unvested restricted stock units ("RSU") granted on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 318,750 of the shares represent unvested restricted stock units ("RSU") granted on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025. 250,000 of the shares represent unvested restricted stock units ("RSU") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").

F2: 125,000 of the shares represent unvested restricted stock units ("RSU") granted on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 318,750 of the shares represent unvested restricted stock units ("RSU") granted on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025. 250,000 of the shares represent unvested restricted stock units ("RSU") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Audentes Therapeutics, Inc.

Report date January 15, 2020 · Filed January 15, 2020

Section 16 reporting ended · disclosed 2020-01-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-01-15 transaction · row 1 1 source row Row 1 · 2020-01-15 · Other · Disposed 89,695 · Balance 0 F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.78 · Expires 2023-09-25	Direct	Reported balance After 2020-01-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-01-15 · Disposition to issuer · Disposed 18,086 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.19 · Expires 2025-05-27	Direct	Reported balance After 2020-01-15 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-01-15 · Disposition to issuer · Disposed 5,605 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.03 · Expires 2026-08-24	Direct	Reported balance After 2020-01-15 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-01-15 · Disposition to issuer · Disposed 9,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.15 · Expires 2027-10-08	Direct	Reported balance After 2020-01-15 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-01-15 · Disposition to issuer · Disposed 9,000 · Balance 0 F3: Reflects the correct exercise price of this option. The exercise price of this option was previously reported as $26.01. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.65 · Expires 2028-06-08	Direct	Reported balance After 2020-01-15 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-01-15 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.74 · Expires 2029-02-06	Direct	Reported balance After 2020-01-15 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-01-15 · Disposition to issuer · Disposed 16,200 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.

Filing footnotes · ownership attribution and instrument terms

F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price.

F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.

F3: Reflects the correct exercise price of this option. The exercise price of this option was previously reported as $26.01.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 08, 2026 Filed Feb 10, 2026 13:00 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	Tax withholdingCommon Stock	36,687	$6.52	$239,199.24	Disclosure SEC source: 0001171843-26-000722 · ownership.xml · nonDerivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,603,336 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F2 · balance_after: 125,000 of the shares represent unvested restricted stock units ("RSU") granted on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 318,750 of the shares represent unvested restricted stock units ("RSU") granted on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025. 250,000 of the shares represent unvested restricted stock units ("RSU") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027. Read SEC document
January 09, 2026 Filed Jan 12, 2026 13:00 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	Tax withholdingCommon Stock	46,777	$5.35	$250,256.95	Disclosure SEC source: 0001171843-26-000205 · ownership.xml · nonDerivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,640,023 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F2 · balance_after: 250,000 of the shares represent unvested restricted stock units ("RSU") granted on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 318,750 of the shares represent unvested restricted stock units ("RSU") granted on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025. 250,000 of the shares represent unvested restricted stock units ("RSU") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027. Read SEC document
January 02, 2026 Filed Jan 5, 2026 21:33 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	GrantStock Option (Right to Buy) · Derivative	2,000,000	$0.00 Strike: $5.17	$0.00	Disclosure SEC source: 0001171843-26-000060 · ownership.xml · derivative · entry 2 Schuetz Thomas J. · CIK 0001591464 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Common Stock · 2,000,000 shares Expires 2036-01-02 F3 · derivative.exercise_date: The options vest over 48 substantially equal monthly installments starting February 2, 2026. Read SEC document
January 02, 2026 Filed Jan 5, 2026 21:33 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	GrantCommon Stock	250,000	$5.17	$1,292,500.00	Disclosure SEC source: 0001171843-26-000060 · ownership.xml · nonDerivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,686,800 F1 · shares: Represents restricted stock units ("RSU") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first vesting on January 2, 2027. F2 · balance_after: 250,000 of the shares represent unvested restricted stock units ("RSU") granted on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 478,125 of the shares represent unvested restricted stock units ("RSU") granted on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025. 250,000 of the shares represent unvested restricted stock units ("RSU") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027. Read SEC document
November 16, 2025 Filed Nov 18, 2025 13:30 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	Tax withholdingCommon Stock	44,025	$4.83	$212,640.75	Disclosure SEC source: 0001171843-25-007400 · ownership.xml · nonDerivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,436,800 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F2 · balance_after: 250,000 of the shares represent unvested restricted stock units ("RSU") granted on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 478,125 of the shares represent unvested restricted stock units ("RSU") granted on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025. Read SEC document
May 27, 2025 Filed May 27, 2025 19:24 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	PurchaseCommon Stock	10,000	$2.11	$21,100.00	Disclosure SEC source: 0001171843-25-003462 · ownership.xml · nonDerivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,480,825 F1 · price: The price reported in Column 4 is the weighted average purchase price. These shares were purchased in two transactions at prices of $2.105 and $2.115 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above. F2 · balance_after: 150,000 of the shares represent unvested RSUs granted on November 16, 2021. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022. 250,000 of the shares represent unvested RSUs granted on February 8, 2023. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 478,125 of the shares represent unvested RSUs granted on January 9, 2024. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025. Read SEC document
February 11, 2025 Filed Feb 13, 2025 22:12 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	GrantStock Option (Right to Buy) · Derivative	1,500,000	$0.00 Strike: $3.65	$0.00	Disclosure SEC source: 0001171843-25-000831 · ownership.xml · derivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500,000 Underlying: CommonStock · 1,500,000 shares Expires 2035-02-11 F1 · derivative.exercise_date: The options vest over 48 substantially equal monthly installments starting March 11, 2025. Read SEC document
February 08, 2025 Filed Feb 11, 2025 15:37 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	Tax withholdingCommon Stock	41,687	$3.50	$145,904.50	Disclosure SEC source: 0001171843-25-000735 · ownership.xml · nonDerivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,470,825 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of common stock. F2 · balance_after: 125,000 of the shares represent unvested RSUs granted on November 16, 2021. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022. 250,000 of the shares represent unvested RSUs granted on February 8, 2023. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 478,125 of the shares represent unvested RSUs granted on January 9, 2024. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025. Read SEC document
January 09, 2025 Filed Jan 13, 2025 13:30 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	Tax withholdingCommon Stock	58,054	$1.86	$107,980.44	Disclosure SEC source: 0001171843-25-000195 · ownership.xml · nonDerivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,512,512 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of common stock. F2 · balance_after: 150,000 of the shares represent unvested RSUs granted on November 16, 2021. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022. 375,000 of the shares represent unvested RSUs granted on February 8, 2023. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 478,125 of the shares represent unvested RSUs granted on January 9, 2024. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025. Read SEC document
February 08, 2024 Filed Feb 9, 2024 17:49 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	Tax withholdingCommon Stock	44,782	$1.45	$64,933.90	Disclosure SEC source: 0001171843-24-000714 · ownership.xml · nonDerivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,570,566 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F2 · balance_after: 300,000 of the shares represents unvested restricted stock units ("RSU") granted on November 16, 2021. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 16, 2022. 375,000 of the shares represents unvested restricted stock units ("RSU") granted on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 637,500 of the shares represents unvested restricted stock units ("RSU") granted on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025. Read SEC document
January 09, 2024 Filed Jan 10, 2024 15:31 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	GrantStock Option (Right to Buy) · Derivative	637,500	$0.00 Strike: $1.93	$0.00	Disclosure SEC source: 0001171843-24-000178 · ownership.xml · derivative · entry 2 Schuetz Thomas J. · CIK 0001591464 · Director · President of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 637,500 Underlying: CommonStock · 637,500 shares Expires 2034-01-08 F3 · derivative.exercise_date: The options vest over 48 substantially equal monthly installments starting February 9, 2024. Read SEC document
January 09, 2024 Filed Jan 10, 2024 15:31 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	GrantCommon Stock	637,500	$1.93	$1,230,375.00	Disclosure SEC source: 0001171843-24-000178 · ownership.xml · nonDerivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · President of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,615,348 F1 · shares: Represents restricted stock units ("RSU") granted to the reporting person on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on January 9, 2025. F2 · balance_after: 300,000 of the shares represents unvested restricted stock units ("RSU") granted on November 16, 2021. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022. 500,000 of the shares represents unvested restricted stock units ("RSU") granted on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 637,500 of the shares represents unvested restricted stock units ("RSU") granted on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025. Read SEC document
November 17, 2023 Filed Nov 21, 2023 19:08 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	Tax withholdingCommon Stock	44,025	$1.50	$66,037.50	Disclosure SEC source: 0001171843-23-007222 · ownership.xml · nonDerivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,977,848 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F2 · balance_after: 12,222 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which will vest on November 30 and December 31, 2023. 300,000 of the shares represents unvested restricted stock units ("RSU") granted to the reporting person on November 16, 2021. 500,000 of the shares represents unvested restricted stock units ("RSU") granted to the reporting person on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022. Read SEC document
March 10, 2023 Filed Mar 10, 2023 18:34 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	PurchaseCommon Stock	10,000	$3.37	$33,700.00	Disclosure SEC source: 0001171843-23-001588 · ownership.xml · nonDerivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,021,873 F1 · price: The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $3.30 to $3.40 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above. F2 · balance_after: 89,051 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 27,937 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 61,114 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 450,000 of the shares represents unvested restricted stock units ("RSU") granted to the reporting person on November 16, 2021. 500,000 of the shares represents unvested restricted stock units ("RSU") granted to the reporting person on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022. Read SEC document
February 27, 2023 Filed Feb 27, 2023 16:39 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	PurchaseCommon Stock	20,000	$3.98	$79,600.00	Disclosure SEC source: 0001171843-23-001175 · ownership.xml · nonDerivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,011,873 F1 · price: The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $3.97 to $3.98 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above. F2 · balance_after: 100,751 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 33,525 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 67,226 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 450,000 of the shares represents unvested restricted stock units ("RSU") granted to the reporting person on November 16, 2021. 500,000 of the shares represents unvested restricted stock units ("RSU") granted to the reporting person on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022. Read SEC document
February 15, 2023 Filed Feb 15, 2023 15:47 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	PurchaseCommon Stock	20,000	$3.86	$77,200.00	Disclosure SEC source: 0001171843-23-000974 · ownership.xml · nonDerivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,991,873 F1 · price: The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $3.76 to $3.89 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above. F2 · balance_after: 100,751 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 33,525 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 67,226 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 450,000 of the shares represents unvested restricted stock units ("RSU") granted to the reporting person on November 16, 2021. 500,000 of the shares represents unvested restricted stock units ("RSU") granted to the reporting person on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022. Read SEC document
February 08, 2023 Filed Feb 9, 2023 21:23 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	GrantStock Option (Right to Buy) · Derivative	700,000	$0.00 Strike: $3.93	$0.00	Disclosure SEC source: 0001171843-23-000851 · ownership.xml · derivative · entry 2 Schuetz Thomas J. · CIK 0001591464 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,000 Underlying: CommonStock · 700,000 shares Expires 2033-02-07 F3 · derivative.exercise_date: The options vest over 48 substantially equal monthly installments starting March 8, 2023. Read SEC document
February 08, 2023 Filed Feb 9, 2023 21:23 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	GrantCommon Stock	500,000	$0.00	$0.00	Disclosure SEC source: 0001171843-23-000851 · ownership.xml · nonDerivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,971,873 F1 · shares: Represents restricted stock units ("RSU") granted to the reporting person on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on February 8, 2024. F2 · balance_after: 100,751 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 33,525 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 67,226 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 450,000 of the shares represents unvested restricted stock units ("RSU") granted to the reporting person on November 16, 2021. 500,000 of the shares represents unvested restricted stock units ("RSU") granted to the reporting person on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022. Read SEC document
January 31, 2023 Filed Jan 31, 2023 15:14 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	PurchaseCommon Stock	20,000	$4.05	$81,000.00	Disclosure SEC source: 0001171843-23-000557 · ownership.xml · nonDerivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,471,873 F1 · balance_after: 112,449 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 39,112 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 73,337 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 450,000 of the shares represents unvested restricted stock units ("RSU") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022. Read SEC document
January 24, 2023 Filed Jan 24, 2023 15:49 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	PurchaseCommon Stock	20,000	$4.19	$83,800.00	Disclosure SEC source: 0001171843-23-000419 · ownership.xml · nonDerivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,451,873 F1 · price: The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $4.07 to $4.33 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above. F2 · balance_after: 112,449 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 39,112 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 73,337 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 450,000 of the shares represents unvested restricted stock units ("RSU") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022. Read SEC document
September 28, 2022 Filed Sep 28, 2022 20:45 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	PurchaseCommon Stock	10,000	$2.32	$23,200.00	Disclosure SEC source: 0001171843-22-006282 · ownership.xml · nonDerivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,431,873 F1 · price: The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.30 to $2.33 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above. F2 · balance_after: 159,246 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 61,462 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 97,784 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units ("RSU") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022. Read SEC document
September 26, 2022 Filed Sep 27, 2022 13:47 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	PurchaseCommon Stock	15,000	$2.27	$34,050.00	Disclosure SEC source: 0001171843-22-006243 · ownership.xml · nonDerivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,421,873 F1 · price: The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.24 to $2.28 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above. F2 · balance_after: 159,246 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 61,462 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 97,784 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units ("RSU") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022. Read SEC document
September 07, 2022 Filed Sep 8, 2022 14:12 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	PurchaseCommon Stock	15,000	$3.03	$45,450.00	Disclosure SEC source: 0001171843-22-006005 · ownership.xml · nonDerivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,406,873 F1 · price: The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $3.02 to $3.04 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above. F2 · balance_after: 159,246 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 61,462 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 97,784 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units ("RSU") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022. Read SEC document
September 01, 2022 Filed Sep 1, 2022 18:37 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	PurchaseCommon Stock	15,000	$2.83	$42,450.00	Disclosure SEC source: 0001171843-22-005905 · ownership.xml · nonDerivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,391,873 F1 · price: The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.77 to $2.89 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above. F2 · balance_after: 159,246 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 61,462 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 97,784 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units ("RSU") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022. Read SEC document
August 17, 2022 Filed Aug 17, 2022 20:06 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	PurchaseCommon Stock	15,000	$3.05	$45,750.00	Disclosure SEC source: 0001171843-22-005700 · ownership.xml · nonDerivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,376,873 F1 · balance_after: 170,946 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 67,050 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 103,896 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units ("RSU") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022. Read SEC document
August 10, 2022 Filed Aug 10, 2022 14:51 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	PurchaseCommon Stock	15,000	$2.64	$39,600.00	Disclosure SEC source: 0001171843-22-005567 · ownership.xml · nonDerivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,361,873 F1 · price: The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.57 to $2.75 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above. F2 · balance_after: 170,946 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 67,050 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 103,896 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units ("RSU") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022. Read SEC document
August 01, 2022 Filed Aug 2, 2022 13:15 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	PurchaseCommon Stock	15,000	$2.58	$38,700.00	Disclosure SEC source: 0001171843-22-005231 · ownership.xml · nonDerivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,346,873 F1 · price: The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.51 to $2.62 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above. F2 · balance_after: 170,946 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 67,050 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 103,896 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units ("RSU") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022. Read SEC document
June 21, 2022 Filed Jun 21, 2022 17:41 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	PurchaseCommon Stock	20,000	$2.80	$56,000.00	Disclosure SEC source: 0001171843-22-004440 · ownership.xml · nonDerivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,331,873 F1 · price: The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.78 to $2.81 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above. F2 · balance_after: 194,345 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 78,225 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 116,120 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units ("RSU") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022. Read SEC document
June 16, 2022 Filed Jun 17, 2022 20:46 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	PurchaseCommon Stock	20,000	$2.34	$46,800.00	Disclosure SEC source: 0001171843-22-004408 · ownership.xml · nonDerivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,311,873 F1 · price: The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.31 to $2.40 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above. F2 · balance_after: 194,345 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 78,225 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 116,120 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units ("RSU") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022. Read SEC document
June 13, 2022 Filed Jun 13, 2022 19:59 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	PurchaseCommon Stock	30,000	$2.29	$68,700.00	Disclosure SEC source: 0001171843-22-004327 · ownership.xml · nonDerivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,291,873 F1 · price: The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.20 to $2.31 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above. F2 · balance_after: 194,345 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 78,225 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 116,120 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units ("RSU") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022. Read SEC document
June 06, 2022 Filed Jun 7, 2022 15:50 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	PurchaseCommon Stock	30,000	$2.83	$84,900.00	Disclosure SEC source: 0001171843-22-004190 · ownership.xml · nonDerivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,261,873 F1 · price: The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.82 to $2.87 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above. F2 · balance_after: 194,345 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 78,225 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 116,120 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units ("RSU") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022. Read SEC document
June 01, 2022 Filed Jun 1, 2022 16:33 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	PurchaseCommon Stock	20,000	$3.03	$60,600.00	Disclosure SEC source: 0001171843-22-004068 · ownership.xml · nonDerivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,231,873 F1 · price: The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.94 to $3.08 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above. F2 · balance_after: 194,345 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 78,225 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 116,120 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units ("RSU") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022. Read SEC document
May 26, 2022 Filed May 26, 2022 18:58 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	PurchaseCommon Stock	20,000	$3.04	$60,800.00	Disclosure SEC source: 0001171843-22-003978 · ownership.xml · nonDerivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,211,873 F1 · price: The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.98 to $3.07 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above. F2 · balance_after: 206,043 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 83,812 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 122,231 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units ("RSU") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022. Read SEC document
May 23, 2022 Filed May 24, 2022 12:09 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	PurchaseCommon Stock	18,355	$2.72	$49,925.60	Disclosure SEC source: 0001171843-22-003899 · ownership.xml · nonDerivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,191,873 F1 · price: The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.51 to $2.89 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above. F2 · balance_after: 206,043 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 83,812 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 122,231 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units ("RSU") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022. Read SEC document
May 17, 2022 Filed May 17, 2022 19:17 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	PurchaseCommon Stock	20,215	$2.47	$49,931.05	Disclosure SEC source: 0001171843-22-003771 · ownership.xml · nonDerivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,173,518 F1 · price: The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.45 to $2.50 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above. F2 · balance_after: 206,043 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 83,812 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 122,231 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units ("RSU") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022. Read SEC document
May 10, 2022 Filed May 10, 2022 18:15 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	PurchaseCommon Stock	27,836	$1.80	$50,104.80	Disclosure SEC source: 0001171843-22-003503 · ownership.xml · nonDerivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,153,303 F1 · price: The price reported is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $1.65 to $1.86 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above. F2 · balance_after: 206,043 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 83,812 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 122,231 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units ("RSU") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022. Read SEC document
February 18, 2022 Filed Feb 23, 2022 22:30 UTC Amendment	Compass Therapeutics, Inc. CMPX · Entity 5614	GrantStock Option (Right to Buy) · Derivative	700,000	$0.00 Strike: $2.40	$0.00	Disclosure SEC source: 0000899243-22-007412 · doc4a.xml · derivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2032-02-17 F1 · derivative.exercise_date: The options vest over 48 substantially equal monthly installments starting 03/17/2022. Read SEC document
February 17, 2022 Filed Feb 19, 2022 00:13 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	GrantStock Option (Right to Buy) · Derivative	700,000	$0.00 Strike: $2.52	$0.00	Disclosure SEC source: 0001171843-22-001211 · ownership.xml · derivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2032-02-16 F1 · derivative.exercise_date: The options vest over 48 substantially equal monthly installments starting 03/17/2022 Read SEC document
November 16, 2021 Filed Nov 19, 2021 00:00 UTC	Compass Therapeutics, Inc. NONE · Entity 5614	GrantCommon Stock	600,000	$0.00	$0.00	Disclosure SEC source: 0000899243-21-045310 · doc4.xml · nonDerivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,125,467 F1 · shares: Represents restricted stock units ("RSU") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022. Read SEC document
February 09, 2021 Filed Mar 1, 2021 15:35 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	GrantStock Option (Right to Buy) · Derivative	700,000	$0.00 Strike: $5.00	$0.00	Disclosure SEC source: 0001209191-21-015099 · doc4.xml · derivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2031-02-09 F1 · derivative.exercise_date: 25% of this option vests on February 9, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document
December 22, 2020 Filed Dec 23, 2020 22:00 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	GrantStock Option (Right to Buy) · Derivative	250,000	$0.00 Strike: $5.00	$0.00	Disclosure SEC source: 0001209191-20-065033 · doc4.xml · derivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2030-12-22 F1 · derivative.exercise_date: 50% of this option is immediately vested and exercisable, with the remainder vesting in 24 substantially equal monthly installments thereafter. Read SEC document
August 06, 2020 Filed Aug 11, 2020 00:50 UTC	Compass Therapeutics, Inc. NONE · Entity 5614	GrantStock Option (Right to Buy) · Derivative	500,000	$0.00 Strike: $5.00	$0.00	Disclosure SEC source: 0000899243-20-021967 · doc4.xml · derivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2030-08-06 F1 · derivative.exercise_date: 50% of this option is immediately vested and exercisable, with the remainder vesting in 24 substantially equal monthly installments thereafter. Read SEC document
June 19, 2020 Filed Jun 24, 2020 01:38 UTC	Compass Therapeutics, Inc. NONE · Entity 5614	PurchaseCommon Stock	97,431	$5.00	$487,155.00	Disclosure SEC source: 0001213900-20-015638 · ownership.xml · nonDerivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,525,467 F1 · balance_after: 586,546 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on February 22, 2018, 3,850.625 shares vest per month with shares fully vested on February 28, 2022, restricted stock award granted on July 3, 2019, 5,587.5 shares vest per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, 25% cliff on December 20, 2020; 6,111.625 shares vest per month thereafter with shares fully vested on December 31, 2023. Read SEC document
January 15, 2020 Filed Jan 15, 2020 13:36 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	Disposition to issuerStock Option (Right to Buy) · Derivative	16,200	Not disclosed Strike: $24.74	Not disclosed	Disclosure SEC source: 0001209191-20-003435 · doc4.xml · derivative · entry 7 Schuetz Thomas J. · CIK 0001591464 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,200 shares Expires 2029-02-06 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document
January 15, 2020 Filed Jan 15, 2020 13:36 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	Disposition to issuerStock Option (Right to Buy) · Derivative	10,000	Not disclosed Strike: $38.65	Not disclosed	Disclosure SEC source: 0001209191-20-003435 · doc4.xml · derivative · entry 6 Schuetz Thomas J. · CIK 0001591464 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2028-06-08 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document
January 15, 2020 Filed Jan 15, 2020 13:36 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	Disposition to issuerStock Option (Right to Buy) · Derivative	9,000	Not disclosed Strike: $26.15	Not disclosed	Disclosure SEC source: 0001209191-20-003435 · doc4.xml · derivative · entry 5 Schuetz Thomas J. · CIK 0001591464 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,000 shares Expires 2027-10-08 F3 · derivative.exercise_price: Reflects the correct exercise price of this option. The exercise price of this option was previously reported as $26.01. F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document
January 15, 2020 Filed Jan 15, 2020 13:36 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	Disposition to issuerStock Option (Right to Buy) · Derivative	9,000	Not disclosed Strike: $15.03	Not disclosed	Disclosure SEC source: 0001209191-20-003435 · doc4.xml · derivative · entry 4 Schuetz Thomas J. · CIK 0001591464 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,000 shares Expires 2026-08-24 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document
January 15, 2020 Filed Jan 15, 2020 13:36 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	Disposition to issuerStock Option (Right to Buy) · Derivative	5,605	Not disclosed Strike: $2.19	Not disclosed	Disclosure SEC source: 0001209191-20-003435 · doc4.xml · derivative · entry 3 Schuetz Thomas J. · CIK 0001591464 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,605 shares Expires 2025-05-27 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document
January 15, 2020 Filed Jan 15, 2020 13:36 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	Disposition to issuerStock Option (Right to Buy) · Derivative	18,086	Not disclosed Strike: $0.78	Not disclosed	Disclosure SEC source: 0001209191-20-003435 · doc4.xml · derivative · entry 2 Schuetz Thomas J. · CIK 0001591464 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,086 shares Expires 2023-09-25 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document
January 15, 2020 Filed Jan 15, 2020 13:36 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	OtherCommon Stock	89,695	$60.00	$5,381,700.00	Disclosure SEC source: 0001209191-20-003435 · doc4.xml · nonDerivative · entry 1 Schuetz Thomas J. · CIK 0001591464 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.